Memantine And Donepezil Hydrochlorides
Generic Name: memantine and donepezil hydrochlorides
Brand Names:
Memantine And Donepezil Hydrochlorides
11 DESCRIPTION Memantine and donepezil hydrochlorides extended-release capsules contain memantine, an orally active NMDA receptor antagonist, as the hydrochloride salt and donepezil, a reversible inhibitor of the enzyme acetylcholinesterase, as the hydrochloride salt.
Overview
11 DESCRIPTION Memantine and donepezil hydrochlorides extended-release capsules contain memantine, an orally active NMDA receptor antagonist, as the hydrochloride salt and donepezil, a reversible inhibitor of the enzyme acetylcholinesterase, as the hydrochloride salt.
Uses
1 INDICATIONS AND USAGE Memantine and donepezil hydrochlorides extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Memantine and donepezil hydrochlorides extended-release capsules are a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 )
Dosage
2 DOSAGE AND ADMINISTRATION • For patients on donepezil hydrochloride 10 mg only, the recommended starting dose of memantine and donepezil hydrochlorides extended-release capsules is 7 mg/10 mg, taken once daily in the evening. The dose should be increased in 7 mg increments to the recommended maintenance dose of 28 mg/10 mg. The minimum recommended interval between dose increases is one week. ( 2.1 ) • Patients on memantine hydrochloride (10 mg twice daily or 28 mg extended-release once daily) and donepezil hydrochloride 10 mg once daily can be switched to memantine and donepezil hydrochlorides extended-release capsules 28 mg/10 mg, taken once daily in the evening.
Side Effects
6 ADVERSE REACTIONS The following serious adverse reactions are discussed below and elsewhere in the labeling. • Cardiovascular Conditions [see Warnings and Precautions ( 5.2 )] • Peptic Ulcer Disease and Gastrointestinal Bleeding [see Warnings and Precautions ( 5.3 )] • Nausea and Vomiting [see Warnings and Precautions ( 5.4 )] • Genitourinary Conditions [ see Warnings and Precautions ( 5.5 )] • Seizures [see Warnings and Precautions ( 5.6 )] • Pulmonary Conditions [see Warnings and Precautions ( 5.7 )] • The most common adverse reactions occurring at a frequency of at least 5% and greater than placebo with memantine hydrochloride extended-release 28 mg/day were headache, diarrhea, and dizziness.
Interactions
7 DRUG INTERACTIONS • Combined use with NMDA antagonists: use with caution. ( 7.2 ) • Memantine and donepezil hydrochlorides extended-release capsules may interfere with anticholinergic medications. ( 7.4 ) • Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. ( 7.5 ) 7.1 Use of Memantine with Drugs That Make the Urine Alkaline The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse reactions.
Warnings
5 WARNINGS AND PRECAUTIONS • Memantine and donepezil hydrochlorides extended-release capsules are likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. ( 5.1 ) • Memantine and donepezil hydrochlorides extended-release capsules may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block. ( 5.2 ) • Monitor patients for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers. ( 5.3 ) • Memantine and donepezil hydrochlorides extended-release capsules can cause diarrhea, nausea, and vomiting. ( 5.4 ) • Memantine and donepezil hydrochlorides extended-release capsules may cause bladder outflow obstructions. 4 CONTRAINDICATIONS Memantine and donepezil hydrochlorides extended-release capsules are contraindicated in patients with known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation.
Pregnancy
8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of memantine and donepezil hydrochlorides extended-release capsules or its active ingredients (memantine hydrochloride and donepezil hydrochloride) in pregnant women. Adverse developmental effects (mortality and decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine or donepezil during pregnancy at doses associated with minimal maternal toxicity.
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Memantine and donepezil hydrochlorides extended-release capsules 21 mg/10 mg, are hard gelatin capsules, with natural body and natural cap imprinted with the logo A313 on the body and 21/10 on the cap in black ink, containing white to off-white beads and are supplied in: Bottle of 30: NDC# 62559-207-30 16.2 Storage and Handling Store at 20° to...
Frequently Asked Questions
What is Memantine And Donepezil Hydrochlorides used for?▼
1 INDICATIONS AND USAGE Memantine and donepezil hydrochlorides extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Memantine and donepezil hydrochlorides extended-release capsules are a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 )
What are the side effects of Memantine And Donepezil Hydrochlorides?▼
6 ADVERSE REACTIONS The following serious adverse reactions are discussed below and elsewhere in the labeling. • Cardiovascular Conditions [see Warnings and Precautions ( 5.2 )] • Peptic Ulcer Disease and Gastrointestinal Bleeding [see Warnings and Precautions ( 5.3 )] • Nausea and Vomiting [see Warnings and Precautions ( 5.4 )] • Genitourinary Conditions [ see Warnings and Precautions ( 5.5 )] • Seizures [see Warnings and Precautions ( 5.6 )] • Pulmonary Conditions [see Warnings and Precautions ( 5.7 )] • The most common adverse reactions occurring at a frequency of at least 5% and greater than placebo with memantine hydrochloride extended-release 28 mg/day were headache, diarrhea, and dizziness.
Can I take Memantine And Donepezil Hydrochlorides during pregnancy?▼
8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of memantine and donepezil hydrochlorides extended-release capsules or its active ingredients (memantine hydrochloride and donepezil hydrochloride) in pregnant women. Adverse developmental effects (mortality and decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine or donepezil during pregnancy at doses associated with minimal maternal toxicity.
What are the important warnings for Memantine And Donepezil Hydrochlorides?▼
5 WARNINGS AND PRECAUTIONS • Memantine and donepezil hydrochlorides extended-release capsules are likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. ( 5.1 ) • Memantine and donepezil hydrochlorides extended-release capsules may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block. ( 5.2 ) • Monitor patients for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers. ( 5.3 ) • Memantine and donepezil hydrochlorides extended-release capsules can cause diarrhea, nausea, and vomiting. ( 5.4 ) • Memantine and donepezil hydrochlorides extended-release capsules may cause bladder outflow obstructions. 4 CONTRAINDICATIONS Memantine and donepezil hydrochlorides extended-release capsules are contraindicated in patients with known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation.
Related Medications
Verapamil Hcl
verapamil hcl
Dosage form: POWDER. Active ingredients: VERAPAMIL HYDROCHLORIDE (1 g/g). Category: BULK INGREDIENT.
Amyl Nitrite
amyl nitrite
Uses: See symptoms on front panel. Relieves hot flash followed by cold sweats *
Ethisterone
ethisterone
Dosage form: POWDER. Active ingredients: ETHISTERONE (1 kg/kg). Category: BULK INGREDIENT.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.